TR200102401T2 - C-21 Değiştirilmiş epotilonlar. - Google Patents

C-21 Değiştirilmiş epotilonlar.

Info

Publication number
TR200102401T2
TR200102401T2 TR2001/02401T TR200102401T TR200102401T2 TR 200102401 T2 TR200102401 T2 TR 200102401T2 TR 2001/02401 T TR2001/02401 T TR 2001/02401T TR 200102401 T TR200102401 T TR 200102401T TR 200102401 T2 TR200102401 T2 TR 200102401T2
Authority
TR
Turkey
Prior art keywords
epothilons
modified
epothilones
thiazole
antifungal
Prior art date
Application number
TR2001/02401T
Other languages
English (en)
Inventor
Hoefle Gerhard
Leibold Thomas
Vite Gregory
Kim Soong-Hoon
Original Assignee
Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de
Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de
Application filed by Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf), Bristol-Myers Squibb Co. filed Critical Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)
Publication of TR200102401T2 publication Critical patent/TR200102401T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Bulus tiazol degiskeni degisiklige ugratilmis olan epotilonlar ile, bunlarin hazirlanmalari için olan yöntemler ve bu epotilonlari içeren antifungal ya da terapetik bilesikler ile ilgilidir.
TR2001/02401T 1999-02-22 2000-02-17 C-21 Değiştirilmiş epotilonlar. TR200102401T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999107588 DE19907588A1 (de) 1999-02-22 1999-02-22 C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de) 1999-07-01 1999-07-01 C-21 Modifizierte Epothilone

Publications (1)

Publication Number Publication Date
TR200102401T2 true TR200102401T2 (tr) 2001-12-21

Family

ID=26051995

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02401T TR200102401T2 (tr) 1999-02-22 2000-02-17 C-21 Değiştirilmiş epotilonlar.

Country Status (37)

Country Link
US (1) US6262094B1 (tr)
EP (1) EP1157023B1 (tr)
JP (1) JP4598957B2 (tr)
KR (1) KR100685336B1 (tr)
CN (1) CN1205208C (tr)
AR (1) AR028815A1 (tr)
AT (1) ATE254615T1 (tr)
AU (1) AU771089B2 (tr)
BG (1) BG64987B1 (tr)
BR (1) BR0008379A (tr)
CA (1) CA2360452C (tr)
CO (1) CO5140093A1 (tr)
CZ (1) CZ301498B6 (tr)
DE (1) DE60006649T2 (tr)
DK (1) DK1157023T3 (tr)
EE (1) EE04852B1 (tr)
ES (1) ES2209831T3 (tr)
GE (1) GEP20033067B (tr)
HK (1) HK1038923B (tr)
HU (1) HUP0200076A3 (tr)
ID (1) ID29829A (tr)
IL (1) IL144501A0 (tr)
LT (1) LT4944B (tr)
LV (1) LV12755B (tr)
MX (1) MXPA01008374A (tr)
MY (1) MY120601A (tr)
NO (1) NO320806B1 (tr)
NZ (1) NZ513629A (tr)
PE (1) PE20001546A1 (tr)
PL (1) PL212545B1 (tr)
PT (1) PT1157023E (tr)
RU (1) RU2253652C2 (tr)
SK (1) SK287200B6 (tr)
TR (1) TR200102401T2 (tr)
TW (1) TWI270546B (tr)
UY (1) UY26024A1 (tr)
WO (1) WO2000050423A1 (tr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753546B2 (en) * 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
EP1319011B1 (de) * 2000-09-22 2012-12-05 Helmholtz-Zentrum für Infektionsforschung GmbH Triazolo-epothilone
IL155306A0 (en) * 2000-10-13 2003-11-23 Univ Mississippi Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
CA2434566A1 (en) 2001-01-25 2002-08-15 Timothy M. Malloy Parenteral formulation containing epothilone analogs
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
IL156988A0 (en) 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
KR20040028720A (ko) * 2001-02-20 2004-04-03 브리스톨-마이어스스퀴브컴파니 치료불응성 종양 치료용 에포틸론 유도체
KR20040025904A (ko) * 2001-03-14 2004-03-26 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 에포틸론 유사체 및화학치료제의 병용
TWI341728B (en) * 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003212457A1 (en) * 2002-03-01 2003-09-16 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
EP1854464A3 (en) * 2002-03-08 2008-06-04 Novartis AG Combinations comprising epothilone derivatives and alkylating agents
IL163774A0 (en) * 2002-03-08 2005-12-18 Univ Newcastle Combinations comprising epothilone derivatives andalkylating agents
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
DE60330651D1 (en) 2002-03-12 2010-02-04 Bristol Myers Squibb Co C3-cyanoepothilonderivate
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
KR20040106422A (ko) * 2002-05-01 2004-12-17 노파르티스 아게 간암 및 다른 암 질병 치료용 에포틸론 유도체
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE450534T1 (de) 2002-08-23 2009-12-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RU2368661C2 (ru) 2002-09-23 2009-09-27 Бристол-Маерс Сквибб Компани Способы получения, выделения и очистки эпотилона b и рентгеноструктурные кристаллические структуры эпотилона в
CN1297258C (zh) * 2002-10-09 2007-01-31 高山生物科学股份有限公司 埃坡霉素d+5－氟尿嘧啶/吉西他滨
WO2004071440A2 (en) 2003-02-06 2004-08-26 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
BRPI0518286A2 (pt) * 2004-11-18 2008-11-11 Bristol Myers Squibb Co microesfera com revestimento entÉrico contendo ixabepilona e sua preparaÇço
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
EP1959952A4 (en) * 2005-11-22 2011-02-23 Scripps Research Inst CHEMICAL SYNTHESIS OF A VERY POWERFUL EPOTHILONE
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2007131366A1 (en) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Iap bir domain binding compounds
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
EP2152717A1 (en) 2007-05-25 2010-02-17 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
WO2009089260A2 (en) 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
SI2276485T1 (sl) * 2008-04-24 2014-10-30 Bristol-Myers Squibb Company Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo
EP2286220A2 (en) * 2008-05-29 2011-02-23 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the co-stimulatory pathway
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
SI2769737T1 (sl) 2009-07-20 2017-06-30 Bristol-Myers Squibb Company Kombinacija anti-ctla4 protitelesa z etoposidom za sinergistično zdravljenje proliferativnih bolezni
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
BR112012010640A2 (pt) 2009-11-05 2016-11-22 Rhizen Pharmaceuticals S A novos moduladores de quinase
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
WO2011146382A1 (en) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
EP3450432A1 (en) 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
WO2012151525A1 (en) 2011-05-04 2012-11-08 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
AP3908A (en) 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
WO2014075391A1 (zh) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
MX2017007097A (es) 2014-12-04 2017-09-05 Bristol Myers Squibb Co Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
BR112017027692A2 (pt) 2015-06-29 2018-10-09 Bristol Myers Squibb Co regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do câncer
CN105153177B (zh) * 2015-09-28 2017-08-08 湖南大学 呋喃并色满肟烯/炔丙基醚及其制备方法与应用
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE301115C (tr)
DE75883C (de) W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen Ofen zur Erzeugung von Cyanammonium
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
AU753546B2 (en) * 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19707303B4 (de) 1997-02-11 2006-05-11 Mitteldeutsches Bitumenwerk Gmbh Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
CN1544436A (zh) 1997-02-25 2004-11-10 ���＼���о����޹�˾��GBF�� 3，7-保护的环氧噻嗪酮-n-氧化物及其制备方法
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (de) 1997-04-18 2002-10-09 Studiengesellschaft Kohle mbH Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
EP1001951B1 (de) 1997-07-16 2002-09-25 Schering Aktiengesellschaft Thiazolderivate, verfahren zur herstellung und verwendung
ATE368036T1 (de) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
CA2356360A1 (en) * 1998-12-23 2000-07-06 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone

Also Published As

Publication number Publication date
BG64987B1 (bg) 2006-11-30
SK287200B6 (sk) 2010-03-08
CA2360452C (en) 2011-07-26
AR028815A1 (es) 2003-05-28
US6262094B1 (en) 2001-07-17
BR0008379A (pt) 2002-09-24
ATE254615T1 (de) 2003-12-15
DE60006649D1 (de) 2003-12-24
KR100685336B1 (ko) 2007-02-23
UY26024A1 (es) 2000-09-29
LT2001086A (en) 2002-04-25
CN1341114A (zh) 2002-03-20
LV12755A (en) 2001-11-20
NO20014017D0 (no) 2001-08-17
IL144501A0 (en) 2002-05-23
MXPA01008374A (es) 2003-06-06
HK1038923A1 (en) 2002-04-04
EP1157023B1 (en) 2003-11-19
HUP0200076A3 (en) 2003-01-28
ES2209831T3 (es) 2004-07-01
WO2000050423A1 (en) 2000-08-31
PL212545B1 (pl) 2012-10-31
EP1157023A1 (en) 2001-11-28
KR20010102199A (ko) 2001-11-15
HK1038923B (zh) 2004-03-19
NO20014017L (no) 2001-10-17
LV12755B (lv) 2002-04-20
PE20001546A1 (es) 2001-03-18
NO320806B1 (no) 2006-01-30
EE200100437A (et) 2002-12-16
BG105830A (en) 2002-03-29
JP4598957B2 (ja) 2010-12-15
CO5140093A1 (es) 2002-03-22
TWI270546B (en) 2007-01-11
ID29829A (id) 2001-10-11
JP2002537395A (ja) 2002-11-05
DK1157023T3 (da) 2004-03-29
LT4944B (lt) 2002-08-26
CN1205208C (zh) 2005-06-08
HUP0200076A2 (hu) 2002-12-28
GEP20033067B (en) 2003-09-25
PL350179A1 (en) 2002-11-18
PT1157023E (pt) 2004-03-31
RU2253652C2 (ru) 2005-06-10
CA2360452A1 (en) 2000-08-31
EE04852B1 (et) 2007-06-15
NZ513629A (en) 2004-01-30
SK10782001A3 (sk) 2002-03-05
AU771089B2 (en) 2004-03-11
DE60006649T2 (de) 2004-09-30
CZ20012991A3 (cs) 2002-01-16
CZ301498B6 (cs) 2010-03-24
MY120601A (en) 2005-11-30
AU3234800A (en) 2000-09-14

Similar Documents

Publication Publication Date Title
TR200102401T2 (tr) C-21 Değiştirilmiş epotilonlar.
DE50306232D1 (de) Ampholytisches copolymer und dessen verwendung
ID23374A (id) Halogenopirimidin
BR0208338A (pt) Derivados de piridina
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
TR200100805T2 (tr) Tetrahidropiridoeterler
ID30046A (id) Kemoterapi kanker dengan asetildinalina digabung dengan gemsitabina, kapestabina atau kisplatin
DE60040981D1 (de) BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
NO20016038L (no) Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme
HK1030218A1 (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same.
TR200201459T2 (tr) Okzkarbazepin içeren süspansiyon
DE60006958T2 (de) Streptograminderivate, ihre herstellung und sie enthaltende zubereitungen
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
DE60015250D1 (de) Versiegelungszusammensetzung
ATE250340T1 (de) 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele
DE59605148D1 (de) Dithiazoldioxide und ihre verwendung als mikrobizide
ATE251619T1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one
DE60002891D1 (de) Streptograminderivate, ihre herstellung und sie enthaltende zubereitungen
DK1459748T3 (da) (S,S)-reboxetin til behandling af perifer neuropati
BR9804596B1 (pt) composiÇço cosmÉtica bifÁsica.
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması
ES1043351Y (es) Calendario de sobremesa.
ITMI990856A1 (it) Composizione funghicida.
NL1018124A1 (nl) Afdichtingselement.